|Assessment Status||Rapid Review complete|
|Indication||As add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy.|
|Rapid review commissioned||11/08/2011|
|Rapid review completed||31/08/2011|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended|
Not considered cost-effective due to non-submission of full pharmacoeconomic evaluation.